CoChat

Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

Open access
the Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, Ruth, de Vries, Elsemieke S., Parés, Albert, Helder, Jeltje, Kemper, E. Marleen, Zwinderman, Koos, Elferink, Ronald P. Oude, Beuers, Ulrich · 2017 · Trials
Cited by 31

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Pruritus (itch) is a frequent, burdensome and difficult-to-treat symptom in patients with cholestasis. Fibrates are currently under investigation for the treatment of primary biliary cholangitis in patients with a suboptimal response to ursodeoxycholic acid. Moreover, there is empirical evidence for a possible antipruritic effect. We aim to prove this in a randomized controlled trial, including patients with cholestatic liver diseases other than primary biliary cholangitis that are accompanied by pruritus. METHODS: A multicenter investigator-initiated, double-blind, randomized placebo-controlled trial to evaluate the effect of bezafibrate on cholestatic pruritus in 84 adult patients with primary biliary cholangitis or primary/secondary sclerosing cholangitis. Primary outcome is the proportion of patients with a reduction of itch intensity of 50% or more (measured on a Visual Analog Scale) after 21 days of treatment with bezafibrate 400 mg qid or placebo. Secondary outcomes include the effect of bezafibrate on a five-dimensional itch score, liver disease-specific quality of life, serum liver tests and autotaxin activity. Safety will be evaluated through serum parameters for kidney function and rhabdomyolysis as well as precise recording of (serious) adverse events. We provide a schematic overview of the study protocol and describe the methods used to recruit and randomize patients, collect and handle data and perform statistical analyses. DISCUSSION: Given its favorable safety profile and anticholestatic properties, bezafibrate may become the new first-line treatment option for treating cholestatic pruritus. TRIAL REGISTRATION: Netherlands Trial Register, ID: NCT02701166 . Registered on 2 March 2016; Netherlands Trial Register, ID: NTR5436 . Registered on 3 August 2015.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13063-017-1966-8

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 31

Metadata

Authors
the Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U.
Venue
Trials
Published
2017-05-23
Volume
18
Issue
1
Pages
230-230
ISSN
1745-6215 (ISSN-L)
OpenAlex
W2619280077
Cited by
31
References
19
FWCI
2.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13063-017-1966-8
The paper
the Netherlands Association for the Study of the Liver (NASL) Cholestatic Liver Diseases Study Group, Bolier, R., de Vries, E. S., Parés, A., Helder, J., Kemper, E. M., Zwinderman, K., Elferink, R. P. O., & Beuers, U. (2017). Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/s13063-017-1966-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.